# Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

> **NCT05844046** · PHASE2 · RECRUITING · sponsor: **Enrico De Toni** · enrollment: 83 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** durvalumab, tremelimumab, bevacizumab

## Key facts

- **NCT ID:** NCT05844046
- **Lead sponsor:** Enrico De Toni
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-06
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05844046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05844046, "Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05844046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*